Projects per year
Abstract
Background: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition resulting from mutations in the alpha-1 antitrypsin (AAT) protein, a major systemic antiproteinase, resulting in reduced/no release of AAT, disrupting the proteinase/antiproteinase balance. A sustained imbalance can cause structural changes to the lung parenchyma, leading to emphysema. Predicting and assessing human responses to potential therapeutic candidates from preclinical animal studies have been challenging. Our aims were to develop a more physiologically relevant in vitro model of the proteinase/antiproteinase balance and assess whether the data generated could better predict the efficacy of pharmacological candidates to inform decisions on clinical trials, together with expected biomarker responses.
Methods: We developed an in vitro model assessing the proteinase/antiproteinase balance by the changes in the fibrinogen cleavage products of neutrophil elastase (NE) and proteinase 3 (PR3). This allowed the assessment of physiological and pharmaceutical neutrophil serine proteinase (NSP) inhibitors to determine the putative threshold at which the maximal effect is achieved.
Results: AAT significantly reduced NE and PR3 activity footprints, with the maximal reduction achieved at concentrations above 10 μM. The inhibitor MPH966 alone also significantly reduced NE footprint generation in a concentration-dependent manner, leveling out above 100 nM but had no effect on the PR3 footprint. At levels of AAT consistent with AATD, MPH966 had an additive effect, reducing the NE activity footprint more than either inhibitor alone.
Conclusion: Our results support an inhibitor threshold above which the activity footprint generation appears resistant to increasing dosage. Our model can support the testing of inhibitors, confirming activity biomarkers as indicators of likely pharmaceutical efficacy, the assessment of NSP activity in the pathophysiology of emphysema, and the likely function of biological or pharmacological inhibitors in disease management.
Methods: We developed an in vitro model assessing the proteinase/antiproteinase balance by the changes in the fibrinogen cleavage products of neutrophil elastase (NE) and proteinase 3 (PR3). This allowed the assessment of physiological and pharmaceutical neutrophil serine proteinase (NSP) inhibitors to determine the putative threshold at which the maximal effect is achieved.
Results: AAT significantly reduced NE and PR3 activity footprints, with the maximal reduction achieved at concentrations above 10 μM. The inhibitor MPH966 alone also significantly reduced NE footprint generation in a concentration-dependent manner, leveling out above 100 nM but had no effect on the PR3 footprint. At levels of AAT consistent with AATD, MPH966 had an additive effect, reducing the NE activity footprint more than either inhibitor alone.
Conclusion: Our results support an inhibitor threshold above which the activity footprint generation appears resistant to increasing dosage. Our model can support the testing of inhibitors, confirming activity biomarkers as indicators of likely pharmaceutical efficacy, the assessment of NSP activity in the pathophysiology of emphysema, and the likely function of biological or pharmacological inhibitors in disease management.
| Original language | English |
|---|---|
| Article number | 1421598 |
| Journal | Frontiers in Pharmacology |
| Volume | 15 |
| DOIs | |
| Publication status | Published - 1 Jul 2024 |
Keywords
- neutrophil elastase
- proteinase 3
- proof of concept
- MPH966
- alpha-1 antitrypsin deficiency
Access to Document
Fingerprint
Dive into the research topics of 'A novel in vitro cell model of the proteinase/antiproteinase balance observed in alpha-1 antitrypsin deficiency'. Together they form a unique fingerprint.-
Efficacy and Mechanism Evaluation -Effectiveness of Electronic Cigarettes compared with varenicline for smoking cessation in patients with COPD and effect on the Lungs (EME-ECAL study)
Scott, A. (Principal Investigator), Sapey, E. (Co-Investigator), Handley, K. (Co-Investigator), Thickett, D. (Co-Investigator), Parekh, D. (Co-Investigator) & Farley, A. (Co-Investigator)
1/03/23 → 28/02/26
Project: Other Government Departments
-
Effectiveness of Electronic Cigarettes compared with combination nicotine replacement therapy for smoking cessation in patients with chronic obstructive pulmonary disease and effect on Lung health (ECAL study).
Scott, A. (Researcher), Handley, K. (Researcher), Sapey, E. (Co-Investigator), Adab, P. (Researcher), Jowett, S. (Researcher), Farley, A. (Principal Investigator), Jordan, R. (Researcher), Parekh, D. (Researcher) & Thickett, D. (Co-Investigator)
1/09/22 → 30/09/25
Project: Other Government Departments
-
Evaluating the impact of E-cigarettes on the innate immune response in chronic obstructive pulmonary disease
Sapey, E. (Co-Investigator), Thickett, D. (Co-Investigator) & Scott, A. (Principal Investigator)
1/10/21 → 30/09/24
Project: Research
-
Does Neutrophil Elastase Inhibitor AZD9668 Protect Against Protease Associated Lung Damage? - Project 2
Sapey, E. (Co-Investigator) & Stockley, R. (Principal Investigator)
1/12/20 → 31/07/23
Project: Research
-
Does hospitalisation of older patients with severe community acquired pneumonia and sepsis lead to long term
Sapey, E. (Co-Investigator), Thickett, D. (Principal Investigator), Richter, A. (Co-Investigator), Patel, J. (Co-Investigator), Mitchell, T. (Co-Investigator) & Scott, A. (Co-Investigator)
1/07/19 → 30/06/23
Project: Research Councils